Wyeth RotaShield fever-related hospitalization rate needs further study -- FDA advisory committee.
WYETH ROTASHIELD HOSPITALIZATION RATE SHOULD BE STUDIED, FDA's Vaccines and Related Biological Products Advisory Committee agreed at a Dec. 12 meeting to review the live oral tetravalent vaccine for the prevention of rotavirus gastroenteritis in infants. The committee voted unanimously that Wyeth-Ayerst's RotaShield is moderately effective in overall rotavirus gastroenteritis prevention and shows greater efficacy in the prevention of severe disease.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth